Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

THE WOODLANDS, Texas, Dec. 14, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues. The trial was the first test of this new anti-inflammatory mechanism of action in patients and was designed to obtain safety and tolerability information and signals of efficacy.  

Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all three doses tested, 70 mg, 110 mg, and 150 mg given once per day, were well tolerated over the 12-week treatment period.  Taken together, the data also suggested that patients treated with 150 mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo).  Patients treated with 70 mg or 110 mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo. Adverse events for all three LX2931 dose groups were predominantly mild-to-moderate, with frequencies similar to the placebo group.

"We believe the preliminary signal of efficacy and the favorable safety profile observed in this trial supports further study
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/24/2014)... 23, 2014  Medical Science Liaisons play a large ... between the medical device industry and key stakeholders, the ... coming years as the device industry relies on them ... research by benchmarking firm, Best Practices, LLC, one area ... edge is by harnessing new technology to enable education. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
(Date:12/24/2014)... Over 700 toys, that’s what ... That is 700 smiling little faces this holiday that ... $6000 in monetary donations was given to the various ... expenses they incur through the year. Some of the ... Child's Haven , Shrine's Children's Hospitals, Toys for Tots ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... 25, 2014 Today, UWDress.com, the famous women’s ... wedding gowns, and launched a site-wide wedding gown promotion. ... wedding gowns in a more unexpected way, the collection should ... popular in the global market, and they are available with ... are offered at discounted prices, up to 75% off; most ...
(Date:12/24/2014)... BambooIndustry.com a famous bamboo flooring company offering bamboo flooring ... announces its multiple layer bamboo panel board collection , ... , Bamboo panel is the product made from 100 ... board features high quality selective bamboo and eco-friendly adhesives ... panel consists of multiple layers of bamboo. , According ...
(Date:12/24/2014)... A new, injectable weight-loss drug has been approved by ... on Tuesday approved Saxenda (liraglutide) for adults who are ... at least one weight-related health condition, such as high ... Patients taking the drug, made by Novo Nordisk, should ... FDA noted. "Obesity is a public health concern ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3
... Negative pressure wound therapy is a new innovation in treating ... for frequent and stressful dressing changes. A new study ... a wide range of applications with children, and can be ... a vacuum system which applies negative suction pressure to the ...
... Bereaved families of firefighters who lost their lives to work- ... relief at last. Ontarios new labor laws state that they ... in order to qualify for compensation due the dead workers ... identify eight types of cancer that will be presumed to ...
... Service, an agency of the New York state government has ... County Hospital as a shameful "chamber of filth, decay, ... Civil Liberties Union, the agency has filed a suit in ... the ward, where patients are subjected to overcrowded conditions, physical ...
... is recalling half-gallon packages of Galliker's Acidophilus Plus Reduced ... milk may be unsafe. It has not been shown ... the raw milk itself to determine the presence or ... is free of infectious organisms. Only products with the ...
... An oral vaccine can prevent mice from developing a brain ... will be presented at the American Academy of Neurology's ... 2007. Prion diseases, which include scrapie, mad cow disease, and ... or cure. ,The disease spreads when an animal ...
... Coast Eagles star Ben Cousins broke his silence for the first ... that he has indeed a problem of substance abuse. ... rehabilitation centre for the past months. He was being treated for ... ,He did not disclose the name of the drug ...
Cached Medicine News:Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 2Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 3Health News:Suit Filed Against Horrors of Psychiatric Ward in New York Hospital 2Health News:Vaccine Prevents Prion Disease in Mice 2Health News:Cousins Recovering from His Substance Abuse Problem 2
... CellTracks® Analyzer II is ... used to enumerate fluorescently ... immunomagnetically selected and aligned. ... the CellTracks® Analyzer II, ...
... These unique Acid Fast ... sputum smear with appropriate background ... containing a positive and negative ... Kinyoun (Cat. No. 353), Ziehl-Neelsen ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Medicine Products: